Compare WTTR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTTR | HRMY |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2017 | 2020 |
| Metric | WTTR | HRMY |
|---|---|---|
| Price | $18.91 | $34.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $16.67 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.4M | 709.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $1,528,930,000.00 | $868,453,000.00 |
| Revenue This Year | $2.11 | $19.75 |
| Revenue Next Year | $4.94 | $12.88 |
| P/E Ratio | $69.16 | ★ $64.00 |
| Revenue Growth | ★ 120.79 | 21.51 |
| 52 Week Low | $7.86 | $25.52 |
| 52 Week High | $20.48 | $40.87 |
| Indicator | WTTR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 62.32 |
| Support Level | $17.82 | $25.92 |
| Resistance Level | $19.39 | $34.99 |
| Average True Range (ATR) | 0.66 | 1.10 |
| MACD | -0.13 | 0.39 |
| Stochastic Oscillator | 55.73 | 75.30 |
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.